How effective is Apelix?

Alpelisibwas released in2019year5month< span>24Obtained FDAapproval for the treatment of advanced or metastatic breast cancer in postmenopausal women and men in combination with fulvestrant. The cancer must be hormone receptor (HR) positive, human epidermal growth factor receptor (2 (her 2)) negative and PIK3CA mutated. The cancer must be detected by an FDA-approved test after progression on an endocrine-based regimen. Apelvis is also indicated for the treatment of adult and pediatric patients 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) requiring systemic therapy.

Background:Activation of phosphatidylinositol-3-kinase (PI3K) pathway by PIK3CA mutation in 28%-46% Hormone receptor-positive (HR+), human epidermal growth factor receptor -2-negative (HER2-) occurs in advanced breast cancer (ABCs) and is associated with poor prognosis. SOLAR-1The trial showed that adding apelixto fulvestrant treatment can reduce PIK3CAmutations, HR+, HER2- ABCprovides a statistically significant and clinically meaningful progression-free survival (PFS) benefit.

Patients and Methods:Patients withHR+, HER2- ABC and whose disease is on aromatase inhibitors (AI) Men and postmenopausal women who have progressed on or after treatment with 1: 1 proportion were randomized to receive apelix (300mg/day) plus fulvestrant (500mg/28days, once on 15days) or placebo plus fulvestrant. Overall survival (OS) in the PIK3CA mutation cohort was assessed by the Kaplan-Meier method and a one-sided stratified log-rank test was performed, and the O‘brien-Fleming efficacy margin was P ≤ 0.0161.

Results:InPIK3CA mutation cohort (n = 341), the median OS of fulvestrant[95%confidence interval (CI)] was 39.3 months (34.1-44.9), placebo-median fulvestrantOS[hazard ratio (HR)= 0.86 (95% CI, 0.64-1.15; P = 0.15). OSThe results did not exceed prespecified efficacy boundaries. Median OS(95% CI) were 37.2 months (28.7-43.6 ) and 22.8 months (19.0-26.8) [HR = 0.68（0.46-1.00)]. Apelix-Fulvestrant and placebo-The median duration of chemotherapy for fulvestrant was 23.3 months (15.2-28.4) and 14.8 respectively.months (10.5-22.6) [HR = 0.72 (0.54-0.95)]. No new safety signals were observed during long-term follow-up.

Conclusions:Although this analysis did not cross the prespecified boundaries of statistical significance, significant differences in PIK3CA mutations, HR+, HER2- Adding apelix to fulvestrant treatment in ABCpatients resulted in a median OS improvement of 7.9 months. Collectively, these results further support the statistically significant prolongation of PFS observed with apelvis plus fulvestrant in this population with a poor prognosis due to PIK3CA mutations. The retail price of the Indian version of the original medicine in pharmacies150mg28 is around three to four thousand per pill. The retail price of the European version in pharmacies is about 150mg56 tablets4 about 10,000 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.